Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.
Business & Industry
- Amgen successfully completes acquisition of Five Prime Therapeutics
- GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
- Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
- Pfizer and BioNTech request regulatory agencies expand emergency use of their COVID-19 vaccine to adolescents
- Valneva reports positive Phase 1/2 data for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001
Research & Development
- SARS-CoV-2: New findings on the persistence of neutralizing antibodies
- Massive fragment screen points way to new SARS-CoV-2 inhibitors
- B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
- COVID-19 causes 'unexpected' cellular response in the lungs
- Clinical trial completion rates decline during COVID-19 pandemic
- Study identifies possible COVID-19 drugs - including several that are FDA-approved
- COVID-19 convalescent plasma with greater antibody levels is safe and shows promise
Conferences & Events
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
- FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
- Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
- AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
- Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
- EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events